BUZZ-AlphaTON Capital skyrockets on blockchain-based cancer drug funding plans
Reuters
13 hours ago
BUZZ-AlphaTON Capital skyrockets on blockchain-based cancer drug funding plans
** Shares of digital asset treasury company AlphaTON Capital Corp ATON.O surge 95.69% to $10.92
** Earlier in session, co's shares hit over 5-month high of $13.80
** Co and its oncology unit Tarus Therapeutics are exploring ways to fund the development of cancer treatments using digital assets
** ATON signs non-binding letter of intent (LOI) to look into tokenizing the financial value of TT-4, a cancer drug being developed to treat mesothelioma
** Unit says first-patient dosing with TT-4 is targeted for Q1 2026
** YTD, the stock has risen ~107%, including session's moves
(Reporting by Krisha Bhatt)
((Krisha.Bhatt@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.